Abstract
In recent years, drug development in oncology switched focus from conventional cytotoxic drugs to targeted therapies. Despite this change in focus, dose selection of anticancer drugs in early drug development is still often solely based on toxicity. Dose selection could be further improved by using both exposure-efficacy and exposure-toxicity relationships
... read more